Meaningful changes to DIR fees are on the horizon—will pharmacies see an increase in reimbursements?
Board-certified pharmacists are better prepared to deal with pediatric patients than others. Here’s why.
FDA approves apalutamide for castration-resistant prostate cancer.
Peter Kreckel recently tried to explain DIR fees to students. Here’s how it went.
Pharmacists are in a unique position to screen patients for frailty. Here are the top risk factors to look for, and what to do when you encounter them.
There is plenty for community pharmacists to worry about, but there is a light at the end of the tunnel.
Pharmacists are finding ways to get reimbursed for clinical services. See what you can do to get paid.